Prognostic value of controlling nutritional status score (CONUT) in patients with colorectal cancer: a systematic review and meta-analysis.
메타분석
1/5 보강
[OBJECTIVES] This study assesses the prognostic value of the controlling nutritional status score (CONUT) in colorectal cancer patients.
- 95% CI 1.70–2.65
- HR 2.12
- 연구 설계 Meta-analysis
APA
Gu W, Li H (2025). Prognostic value of controlling nutritional status score (CONUT) in patients with colorectal cancer: a systematic review and meta-analysis.. BMC cancer, 25(1), 1721. https://doi.org/10.1186/s12885-025-15097-6
MLA
Gu W, et al.. "Prognostic value of controlling nutritional status score (CONUT) in patients with colorectal cancer: a systematic review and meta-analysis.." BMC cancer, vol. 25, no. 1, 2025, pp. 1721.
PMID
41193995
Abstract
[OBJECTIVES] This study assesses the prognostic value of the controlling nutritional status score (CONUT) in colorectal cancer patients.
[METHODS] A systematic search was performed in PubMed, Embase, Web of Science, and Cochrane databases until December 2024. The primary outcomes were overall survival (OS), disease-free survival (DFS), and relapse-free survival (RFS). Hazard ratios (HR) with 95% confidence intervals (CI) were used for data synthesis. Sensitivity and subgroup analyses were used to assess the results stability and heterogeneity sources. All statistical analyses were performed using Review Manager 5.4 and STATA 15.1.
[RESULTS] Fifteen studies involving 9,258 colorectal cancer patients were included. Meta-analysis showed higher CONUT scores were linked to shorter OS (HR: 2.12; 95% CI: 1.70–2.65; < 0.00001), DFS (HR: 1.71; 95% CI: 1.11–2.64; = 0.02), and RFS (HR: 1.75; 95% CI: 1.39–2.20; < 0.00001). Sensitivity analysis confirmed the stability of CONUT’s prognostic value for OS, DFS, and RFS. Subgroup analysis identified the CONUT cut-off value as a major factor contributing to OS heterogeneity.
[CONCLUSIONS] CONUT appears to be associated with worse prognosis in colorectal cancer patients. However, due to potential publication bias, heterogeneity, and the retrospective study design, further large-scale, multicenter, prospective cohort studies are required to confirm its prognostic utility.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15097-6.
[METHODS] A systematic search was performed in PubMed, Embase, Web of Science, and Cochrane databases until December 2024. The primary outcomes were overall survival (OS), disease-free survival (DFS), and relapse-free survival (RFS). Hazard ratios (HR) with 95% confidence intervals (CI) were used for data synthesis. Sensitivity and subgroup analyses were used to assess the results stability and heterogeneity sources. All statistical analyses were performed using Review Manager 5.4 and STATA 15.1.
[RESULTS] Fifteen studies involving 9,258 colorectal cancer patients were included. Meta-analysis showed higher CONUT scores were linked to shorter OS (HR: 2.12; 95% CI: 1.70–2.65; < 0.00001), DFS (HR: 1.71; 95% CI: 1.11–2.64; = 0.02), and RFS (HR: 1.75; 95% CI: 1.39–2.20; < 0.00001). Sensitivity analysis confirmed the stability of CONUT’s prognostic value for OS, DFS, and RFS. Subgroup analysis identified the CONUT cut-off value as a major factor contributing to OS heterogeneity.
[CONCLUSIONS] CONUT appears to be associated with worse prognosis in colorectal cancer patients. However, due to potential publication bias, heterogeneity, and the retrospective study design, further large-scale, multicenter, prospective cohort studies are required to confirm its prognostic utility.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15097-6.
같은 제1저자의 인용 많은 논문 (5)
- Biomimetic Catalase-Templated Nanoprobes for MRI-Guided Oxygen-Supplemented Photodynamic Therapy in Breast Cancer.
- The pectoralis major index: a novel computed tomography biomarker for low thoracic muscle mass and eastern cooperative oncology group performance status in lung cancer patients.
- Inhibiting NAT10 suppresses hepatocellular carcinoma progression by reducing Nrf2 mRNA stability and increasing oxidative stress.
- Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma.
- Impact of Transoral Radiofrequency Microsurgery and Radiotherapy on Long-term Swallowing Function in Patients with T1 Glottic Carcinoma.